DexCom (NASDAQ:DXCM) Price Target Increased to $485.00 by Analysts at Citigroup

DexCom (NASDAQ:DXCM) had its price objective increased by Citigroup from $440.00 to $485.00 in a research report report published on Wednesday morning, The Fly reports. The firm currently has a buy rating on the medical device company’s stock.

Several other equities research analysts have also recently weighed in on the company. JPMorgan Chase & Co. increased their target price on DexCom from $360.00 to $450.00 and gave the company an overweight rating in a report on Monday, July 27th. Cowen increased their target price on DexCom from $430.00 to $450.00 and gave the company an outperform rating in a report on Tuesday, July 7th. BidaskClub upgraded DexCom from a buy rating to a strong-buy rating in a report on Wednesday, July 22nd. Piper Sandler increased their price objective on DexCom from $450.00 to $465.00 and gave the stock an overweight rating in a report on Wednesday. Finally, Oppenheimer assumed coverage on DexCom in a report on Tuesday, July 28th. They issued a buy rating and a $445.00 price objective for the company. Seven investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. DexCom has an average rating of Buy and an average target price of $394.95.

Shares of DexCom stock opened at $435.54 on Wednesday. The company has a current ratio of 7.58, a quick ratio of 5.41 and a debt-to-equity ratio of 1.28. The firm has a market capitalization of $41.70 billion, a PE ratio of 198.88, a price-to-earnings-growth ratio of 4.70 and a beta of 0.79. The business’s 50-day moving average price is $410.52 and its 200-day moving average price is $325.07. DexCom has a 12 month low of $138.28 and a 12 month high of $446.50.

DexCom (NASDAQ:DXCM) last issued its earnings results on Tuesday, July 28th. The medical device company reported $0.79 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.48. The company had revenue of $451.80 million during the quarter, compared to analysts’ expectations of $415.21 million. DexCom had a return on equity of 29.01% and a net margin of 11.93%. DexCom’s quarterly revenue was up 34.3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.08 EPS. As a group, analysts predict that DexCom will post 2.43 earnings per share for the current fiscal year.

In other DexCom news, insider Andrew K. Balo sold 6,522 shares of DexCom stock in a transaction on Monday, June 15th. The stock was sold at an average price of $366.47, for a total value of $2,390,117.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Shelly Ramasamy Selvaraj sold 400 shares of DexCom stock in a transaction on Monday, May 11th. The stock was sold at an average price of $404.05, for a total value of $161,620.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 63,293 shares of company stock valued at $24,266,963. 0.69% of the stock is owned by corporate insiders.

Several institutional investors have recently bought and sold shares of DXCM. National Asset Management Inc. purchased a new position in DexCom during the second quarter valued at $904,000. Comerica Bank lifted its position in DexCom by 41.4% during the second quarter. Comerica Bank now owns 32,699 shares of the medical device company’s stock valued at $13,934,000 after purchasing an additional 9,569 shares in the last quarter. Edmonds Duncan Registered Investment Advisors LLC purchased a new position in DexCom during the second quarter valued at $223,000. Dixon Hubard Feinour & Brown Inc. VA lifted its position in DexCom by 1.2% during the second quarter. Dixon Hubard Feinour & Brown Inc. VA now owns 5,375 shares of the medical device company’s stock valued at $2,246,000 after purchasing an additional 65 shares in the last quarter. Finally, Sigma Planning Corp purchased a new position in DexCom during the second quarter valued at $318,000. 97.08% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Recommended Story: How Do You Make Money With Penny Stocks?

The Fly

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.